Director of Assay Strategy and Development
BioMarin Pharmaceutical Inc.
Andrew C. Melton, PhD, leads the Assay Strategy and Development group within Bioanalytical Sciences at BioMarin Pharmaceutical, Inc. The Assay Strategy and Development group develops and validates pharmacokinetic, pharmacodynamic, biomarker and immunogenicity assays for non-clinical and clinical programs. We constantly evaluate and selectively acquire game-changing technologies to innovate and accelerate drug development. We also determine the optimal internal vs. outsourcing strategy that accommodates program timelines, regulatory commitments, and highest possible quality of data. In the past eight years at BioMarin Pharmaceutical, Inc., Andrew has served as the bioanalytical representative on development teams for enzyme replacement therapies, an exon skipping antisense oligonucleotide and a gene therapy. He received his PhD in Molecular, Cellular, and Integrative Physiology from University of California, Los Angeles, where he studied the cell signaling pathways that regulate contraction and migration of hepatic stellate cells. He then investigated mechanisms of TGFβ activation in mouse models of multiple sclerosis and lung fibrosis as a postdoc at University of California, San Francisco.